Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 878-886

  Postma, Maarten J ^a   Kappelhoff, Bregt S ^b   Van Hulst, Marinus ^a,c   Brouwers, Jacobus R B J ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MARTINI HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anticoagulation; Dabigatran etexilate; Economic evaluation; Venous thrombosis

Indexed keywords

DABIGATRAN ETEXILATE; DALTEPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; COST MINIMIZATION ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEPARIN INDUCED THROMBOCYTOPENIA; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; NETHERLANDS; ORTHOPEDIC SURGERY; PRIMARY PREVENTION; SURGICAL PATIENT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NETHERLANDS; ORTHOPEDICS; POSTOPERATIVE COMPLICATIONS; PRIMARY PREVENTION; PYRIDINES; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 84865203107     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.691144     Document Type: Article

References (37)

1. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism. American college of chest physicians evidence-based clinical practice guidelines. 8th edn. Chest 2008;133(6 Suppl):381S-453S
2. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A metaanalysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465-71
3. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-Analysis of the randomised trials. Lancet 2001;358:9-15
4. Ettema HB, Hoppener MR, Büller HR, et al. Tromboprofylaxe in de orthopedische chirurgie: Inzichten en onzekerheden. Ned Tijdschr Geneeskd 2003;147:1842-7 in Dutch
5. Hill J, Treasure T; on behalf of the National Clinical Guideline Center for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: Summary of NICE guidance. BMJ 2010;340:259-260
6. Biiller HR; Richtlijn diagnostiek, preventie en behandeling van veneuze tromboembolie en secundaire preventie van arteriële trombose. Kwaliteitsinstituut voor de Gezondheidszorg CBO/Nederlands Huisartsen Genootschap. Utrecht 2008. www.cbo.nl/Downloads/492/rl-stol-09.pdf. Accessed August 5, 2010
7. Struijk-Mulder MC, Ettema HB, Verheyen CC, et al. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemostas 2010;8:678-83
8. National Joint Registry for England and Wales 5th Annual Report. 2008; http://www.njrcentre.org.uk/njrcentre/default.aspx. Accessed November 4, 2010
9. Pharmo Institute. Prevention of thromboembolic disease following knee or hip replacement: 'burden of illness'. Utrecht: Pharmo Institute, 2008. http://www.pharmo.nl/frames.php?htmlpagenavigatie/reports.htm. Accessed June 8, 2010
10. Kappelhoff BS. Primaire preventie van veneuze trombo-embolieën na totale heup- of knievervangende operaties: 'burden of illness'. Pharm Weekbl Wet Platform 2009;4:128-34 in Dutch
11. Anderson Jr. FA, Hirsh J, White K, et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: Findings from the Hip and Knee registry. Chest 2003;124(Suppl):349S- 56S
12. Colwell Jr. CW, Pulido P, Hardwick ME, et al. Patient compliance with outpatient prophylaxis: An observational study. Orthopedics 2005;28:143-7
13. Spahn G. Compliance with self-Administration of heparin injections in outpatients. Eur J Trauma 2002;28:104-9
14. Muntz JE, Hultburg R. Safety syringes can reduce the risk of needlestick injuries in venous thromboembolism prophylaxis. J Surg Orthop Adv 2004;13:15-19
15. Ettema HB, Hoppener MR, Henny CP, et al. Compliance of Dutch orthopedic departments with national guidelines of thromboprophylaxis. A survey of Dutch orthopedic thromboprophylaxis. Acta Orthop 2005;76:99-103
16. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised double-blind, non-inferiority trial. Lancet 2007;370:949-56
17. Eriksson BI, Dalh OE, Rosencher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous tromboembolism after total knee replacement: The RE-MODEL randomized trial. J Tromb Haemost 2007;5:2178-85
18. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthoplasty: A pooled analysis of three trials. Thromb Res 2010;126:175-82
19. National Collaborating Centre for Acute Care (NCC-AC). Venous thromboembolism: The prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing orthopaedic surgery and other high-risk surgical procedures. London: National Collaborating Centre for Acute Care, 2007. http://www.rcseng.ac.uk/publications/docs/venous-thrombo.html. Accessed November 4, 2010
20. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. New Engl J Med 2006;355:809-17
21. Health Care Insurance Board. Dutch pharmacoeconomic guidelines 2004 in Dutch. Amstelveen: Health Care Insurrance Board, 2003. http://www.cvz.nl/ resources/FARM-richtlijnen-farmaco-economisch-onderzoek-2006-tcm28-19118.pdf. Accessed August 5, 2010
22. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Guideline for costing research, methods and standardized prices for economic evaluations in health care in Dutch. Diemen: Health Care Insurance Board, 2004. http://www.cvz.nl/resources/feo-handleiding-kostenonderzoek2004-tcm 28-17013.pdf. Accessed December 21, 2010
23. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2008
24. http://www.fk.cvz.nl/. Accessed August 5, 2010
25. Nederlandse Orthopaedische Vereniging. Diagnostiek en behandeling van heup- en knieartrose, richtlijn in Dutch. Nijmegen: Nederlandse Orthopaedische Vereniging, 2007
26. National Collaborating Centre for Acute Care (NCC-AC). Venous thromboembolism: The prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing orthopaedic surgery and other high-risk surgical procedures. 2007
27. http://www.medicijnkosten.nl/. Accessed December 20, 2010
28. Rice L. Heparin-Induced Thrombocytopenia. Myths and misconceptions. Arch Intern Med 2004;164:1961-4
29. Oliveira GBF, Crespo EM, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008;168:94-102
30. Ten Berg M, Huisman A, van den Bemt P, et al. Case-finding of possible heparin-induced thrombocytopenia in an academic teaching hospital by linking laboratory and medication data. Pharmacoepidemiol Drug Saf 2007;16:S51
31. Institute for Medical Technology Assessment. Cost analysis of treatment of adverse events related to treatment of patients with CML. Rotterdam: Institute for Medical Technology Assessment, Erasmus MC, 2007. Report 07.99 (data on file)
32. Wolowacz SE, Hess N, Brennan VK, et al. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery. Current Med Res Opinion 2008;24:2993-3006
33. Hoomans T, van der Roer N, Severens JL, et al. Kosteneffectiviteit van Nieuwe Geneesmiddelen; van belang bij geneesmiddelenvergoeding, maar voor verbetering vatbaa (in Dutch). Nederlands Tijdschrift voor Geneeskunde 2010;154:A958
34. www.cvz.nl. Accessed December 21, 2010
35. Boersma C, Broer ACM, Kappelhoff BS, et al. Problemen bij subcutane toediening van laagmoleculairgewichtheparines na totale heup- en knievervangende operaties in Dutch. Pharm Weekbl 2010;4:20-4
36. Dranitsaris G, Jelincic V, Choe Y. Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement. Thromb J 2001;9:3
37. Smythe MA, Koerber JM, Mattson JC. Identifying the incidence of recognized heparin induced thrombocytopenia in a large tertiary care teaching hospital. Chest 2007;131:1644-9